Trial
NCT00657449
A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain
Phase IVTERMINATEDSAFETYConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Acute Pain
Intervention
valdecoxib
Why stopped
See termination reason in detailed description.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-30